Our lead product is a microfluidic-engineered liposomal formulation of Doxorubicin, created to address the well-known limitations of conventional chemotherapy, including severe systemic toxicity, cardiotoxicity, and inefficient tumour targeting.

While Doxorubicin remains one of the most effective and widely used anticancer agents, its clinical utility is constrained by these side effects. NanoLipo’s technology is designed to overcome these challenges without reinventing the drug itself.

Our product provides a safer and more effective treatment for a range of cancers, including:

- Metastatic breast cancer

- Ovarian cancer

- Multiple myeloma

- AIDS-related Kaposi’s sarcoma

Unlike traditional batch liposome production, NanoLipo’s continuous-flow microfluidic process enables consistent, scalable, and GMP-compatible manufacturing. This approach reduces batch-to-batch variability, lowers cost of goods, and provides a robust platform that can be extended to additional oncology agents in the future.

A Scalable Drug-Delivery Platform

NanoLipo is not simply developing a single product.

We are building a scalable drug-delivery platform capable of transforming how existing and future cancer therapies perform in the body, with meaningful benefits for patients, healthcare systems, and society.

Using adaptable microfluidic processes, we enable the production of precise and consistent liposomal drug formulations that can be applied across a wide range of chemotherapies and future biologics. This approach addresses long-standing challenges such as toxicity, limited targeting, and inefficient delivery.

By improving how cancer medicines reach tumours, the platform supports safer treatments, fewer clinical complications, and expanded therapeutic options. This enables a new generation of oncology solutions defined by precision, efficiency, and meaningful clinical outcomes.